The acquisition of Nexus Medical is being leveraged through existing NICU sales channels, exceeding initial integration expectations.Profitability in 2025 was significantly obscured by tariff impacts, prompting a comprehensive internal cost containment and pricing strategy to protect margins.Surgical pain performance was hindered by slower-than-anticipated hospital implementation of the NOPAIN Act reimbursement, despite Avanos holding several approved devices.The Pain Management portfolio saw double-digit g ...

Pacitti said the SNS portfolio delivered “strong above market” performance in 2025, growing over 8% organically year over year. He cited strength across long-term, short-term, and neonatal enteral feeding, including support from Avanos’s “Go Direct” transition in the U.K. that was executed in the third quarter of 2025.In the quarter, Avanos reported $0.29 in adjusted diluted EPS and $28 million of adjusted EBITDA. Adjusted gross margin was 53.4% and adjusted SG&A was 39.1% of revenue. For the full year, adj ...

分组1 - Integer reported quarterly earnings of $1.76 per share, exceeding the Zacks Consensus Estimate of $1.7 per share, and up from $1.43 per share a year ago, representing an earnings surprise of +3.62% [1] - The company posted revenues of $472.06 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.04%, and an increase from $449.5 million year-over-year [2] - Integer has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has gained approximately 10.3% since the beginning of the year, compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $426.48 million, and for the current fiscal year, it is $6.32 on revenues of $1.84 billion [7] - The Medical - Instruments industry, to which Integer belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Tactile Systems Technology (TCMD) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.44 per share, and showing an increase from $0.40 per share a year ago, representing an earnings surprise of +3.77% [1] - The company achieved revenues of $103.59 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 10.52%, and up from $85.58 million in the same quarter last year [2] - Tactile Systems Technology has outperformed consensus EPS estimates three times over the last four quarters [2] 分组2 - The stock has underperformed the market, losing about 8.8% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $68.67 million, and for the current fiscal year, it is $0.97 on revenues of $345.33 million [7] - The Medical - Instruments industry, to which Tactile Systems Technology belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Waters reported quarterly earnings of $4.53 per share, exceeding the Zacks Consensus Estimate of $4.5 per share, and up from $4.1 per share a year ago, representing an earnings surprise of +0.74% [1] - The company achieved revenues of $932.36 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.55%, and an increase from $872.71 million year-over-year [2] - Over the last four quarters, Waters has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Waters shares up about 0.4% year-to-date compared to the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $2.54 on revenues of $713.34 million, and for the current fiscal year, it is $14.25 on revenues of $3.36 billion [7] - The Medical - Instruments industry, to which Waters belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

分组1 - Ensign Group (ENSG) reported quarterly earnings of $1.82 per share, exceeding the Zacks Consensus Estimate of $1.75 per share, and up from $1.49 per share a year ago [1] - The earnings surprise for this quarter was +4.00%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - The company posted revenues of $1.36 billion for the quarter, which was below the Zacks Consensus Estimate by 0.53%, but an increase from $1.13 billion year-over-year [3] 分组2 - Ensign Group shares have declined approximately 0.3% since the beginning of the year, while the S&P 500 has gained 1.1% [4] - The current consensus EPS estimate for the upcoming quarter is $1.73 on revenues of $1.35 billion, and for the current fiscal year, it is $7.09 on revenues of $5.64 billion [8] - The Medical - Nursing Homes industry, to which Ensign Group belongs, is currently ranked in the top 12% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9]

Core Viewpoint - Thermo Fisher Scientific reported strong quarterly earnings, exceeding expectations and showing growth compared to the previous year [1][2][3]. Financial Performance - The company achieved earnings of $6.57 per share, surpassing the Zacks Consensus Estimate of $6.43 per share, and up from $6.1 per share a year ago [1]. - Revenues for the quarter reached $12.22 billion, exceeding the Zacks Consensus Estimate by 2.28%, and up from $11.4 billion year-over-year [3]. Earnings Surprises - The earnings surprise for the latest quarter was +2.13%, following a previous surprise of +5.27% when actual earnings were $5.79 per share against an expectation of $5.5 per share [2]. Stock Performance - Thermo Fisher shares have increased approximately 4.9% since the beginning of the year, outperforming the S&P 500, which gained 1.9% [4]. Future Outlook - The company's earnings outlook is mixed, with current consensus EPS estimates of $5.57 for the upcoming quarter and $24.58 for the current fiscal year [8]. - The Zacks Rank for Thermo Fisher is currently 3 (Hold), indicating expected performance in line with the market [7]. Industry Context - The Medical - Instruments industry, to which Thermo Fisher belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable environment for performance [9].

Core Insights - Marisol Angelini has been appointed as the Chair of the Board for NACD Atlanta, emphasizing the importance of governance excellence and director effectiveness in her role [1][6]. Leadership and Experience - Marisol Angelini serves as a C-suite advisor and executive mentor at the Ariel Group, focusing on leadership development for senior executives [2]. - She has held senior leadership roles at The Coca-Cola Company, including CMO/VP of Marketing and General Manager of the global Glaceau business, contributing to multiple acquisitions and profitable growth [4]. - Edwina Payne, a new board member, brings over three decades of experience in technology, supply chain, and business transformation, with expertise in digital transformation and M&A integration [8][15]. - Stephen Powell, another new board member, has extensive experience in consumer-facing private and public companies, focusing on governance and capital investment [16][22]. Board Composition and Contributions - The NACD Atlanta Board welcomes Edwina Payne and Stephen Powell, whose combined expertise in technology, governance, and financial advisory will enhance the board's strategic capabilities [7][22]. - Edwina Payne has served on various boards, including Royal Neighbors of America and Sunrise Banks, providing oversight in financial integrity and risk management [9]. - Stephen Powell has a background in investment banking and corporate finance, having held senior advisory roles and served on multiple boards, contributing to governance and strategic initiatives [19][20]. NACD's Role and Mission - The National Association of Corporate Directors (NACD) empowers over 21,000 directors, focusing on enhancing boardroom practices and strengthening investor trust [23]. - NACD has been a recognized authority in corporate governance for over 40 years, fostering collaboration among directors and stakeholders [23].

Core Insights - The article highlights the investment strategies and achievements of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and the development of a system called "Victory Formation" for identifying stocks based on supply/demand imbalances [1]. Group 1: Investment Strategies - Paul Franke recommends a diversified approach by owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1]. - The "Bottom Fishing Club" articles focus on deep value candidates or stocks that are experiencing a significant reversal in technical momentum [1]. - The "Volume Breakout Report" articles discuss positive trend changes supported by strong price and volume trading action [1]. Group 2: Performance and Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and was recognized for his stock market and commodity macro views [1]. - He achieved a top ranking in the Motley Fool® CAPS stock picking contest during parts of 2008 and 2009, out of over 60,000 portfolios [1]. - As of December 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance based on suggestions made over the last five years [1].

Company Overview - Avanos Medical, Inc. is a medical technology company providing device solutions across multiple regions including North America, Europe, and Asia Pacific [2] - The company operates in the pain management and enteral feeding sectors, characterized by safety, clinician familiarity, and regulatory stability [2] Market Position - Avanos was spun out of Kimberly-Clark and thrives in regulation-heavy niches that create high barriers to entry and predictable cash flows [3] - The company's products, such as the Coolief radiofrequency ablation system and On-Q pain pumps, are integrated into national hospital pain protocols, making them difficult to displace [3] Competitive Advantages - The Corpak brand is a leader in enteral feeding, trusted by healthcare professionals due to consistent safety data [4] - Coolief's status as the first FDA-cleared RF system for osteoarthritis pain enhances payer and physician loyalty, while the company's reputation in high-risk care settings builds institutional trust [4] Growth Drivers - Macro trends such as aging populations and a shift towards non-opioid pain solutions support Avanos's growth [4] - The company benefits from procedural inertia and long procurement cycles, which protect its market share [4] Financial Metrics - Key metrics include Coolief utilization in orthopedic and spine centers, gross margin expansion from higher-margin therapies, and a record of recall-free operations [5] - The stock was trading at $11.97 with a trailing P/E of 164.60 as of January 12th [1] Investment Thesis - Avanos is viewed as a low-beta, reliable franchise in an opioid-averse environment, where hospitals prioritize predictability over disruption [5] - The company is seen as quietly compounding by monetizing stability anchored in safe, reimbursed, repeatable care [5]